Ignite Creation Date:
2025-12-25 @ 5:08 AM
Ignite Modification Date:
2025-12-26 @ 4:12 AM
Study NCT ID:
NCT04811027
Status:
COMPLETED
Last Update Posted:
2025-12-11
First Post:
2021-03-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Sponsor:
Immutep S.A.S.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-11-05
Completion Date Type:
ACTUAL
First Submit Date:
2021-03-19
First Submit QC Date:
None
Study First Post Date:
2021-03-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-10-31
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2025-12-09
Last Update Post Date:
2025-12-11
Last Update Post Date Type:
ESTIMATED